Zobrazeno 1 - 10
of 11
pro vyhledávání: '"John-Paul Gallivan"'
Autor:
Donald M. Jensen, Tarik Asselah, Douglas Dieterich, Graham R. Foster, Mark S. Sulkowski, Stefan Zeuzem, Parvez Mantry, Eric M. Yoshida, Christophe Moreno, Denis Ouzan, Mark Wright, Luis E. Morano, Robert Buynak, Marc Bourlière, Tarek Hassanein, Shuhei Nishiguchi, Jia-Horng Kao, Masao Omata, Seung W. Paik, David K. Wong, Edward Tam, Kelly Kaita, S. Victor Feinman, Jerry O. Stern, Joseph Scherer, Anne-Marie Quinson, Florian Voss, John-Paul Gallivan, Wulf O. Böcher, Peter Ferenci
Publikováno v:
Annals of Hepatology, Vol 15, Iss 3, Pp 333-349 (2016)
Introduction & aim. Faldaprevir is a potent once-daily (q.d.) hepatitis C virus (HCV) NS3/4A protease inhibitor. The STARTVerso1 and STARTVerso2 phase 3 studies evaluated faldaprevir plus peginterferon alfa-2a/ribavirin (PegIFN/RBV) in treatment-naï
Externí odkaz:
https://doaj.org/article/dda945401c9c4406bf45486119425e6e
Autor:
Tarik Asselah, Stefan Zeuzem, Vicente Soriano, Jean-Pierre Bronowicki, Ansgar W Lohse, Beat Müllhaupt, Marcus Schuchmann, Marc Bourlière, Maria Buti, Stuart K Roberts, Edward J Gane, Jerry O Stern, Florian Voss, Patrick Baum, John-Paul Gallivan, Wulf O Böcher, Federico J Mensa
Publikováno v:
PLoS ONE, Vol 10, Iss 12, p e0144004 (2015)
BACKGROUND & AIM:Whether inosine triphosphatase (ITPA) gene polymorphisms predict anemia during interferon-free therapy in chronic hepatitis C virus (HCV)-infected patients is unknown. We examined the relationship between two ITPA polymorphisms, anem
Externí odkaz:
https://doaj.org/article/82c7b499dfde4c6ab03bbb8f9340a6f3
Autor:
Federico J. Mensa, Jerry O. Stern, Vicente Soriano, Maria Buti, Jawahar Taunk, Jean-François Dufour, Richard Vinisko, Parvez S. Mantry, Wulf O. Böcher, John-Paul Gallivan, Robert Buynak, Stefan Zeuzem
Publikováno v:
Liver International. 35:417-421
BACKGROUND & AIMS The safety and efficacy of the interferon-free combination of faldaprevir (NS3/A4 protease inhibitor), deleobuvir (BI 207127, non-nucleoside polymerase inhibitor), and ribavirin in treatment-naive patients chronically infected with
Autor:
Jerry O. Stern, Joseph Scherer, Seung Woon Paik, Mark S. Sulkowski, Parvez S. Mantry, Kelly Kaita, Florian Voss, L. Morano, Eric M. Yoshida, Robert Buynak, Anne Marie Quinson, Jia-Horng Kao, Marc Bourlière, Tarik Asselah, Masao Omata, S. Victor Feinman, David Wong, Douglas T. Dieterich, Shuhei Nishiguchi, Denis Ouzan, Wulf O. Böcher, Stefan Zeuzem, Christophe Moreno, Graham R. Foster, Tarek Hassanein, Donald M. Jensen, Mark Wright, John Paul Gallivan, Edward Tam, Peter Ferenci
Publikováno v:
Annals of Hepatology, Vol 15, Iss 3, Pp 333-349 (2016)
Introduction & aim. Faldaprevir is a potent once-daily (q.d.) hepatitis C virus (HCV) NS3/4A protease inhibitor. The STARTVerso1 and STARTVerso2 phase 3 studies evaluated faldaprevir plus peginterferon alfa-2a/ribavirin (PegIFN/RBV) in treatment-naï
Autor:
John P. Sabo, Ansgar W. Lohse, Maria Buti, Stefan Zeuzem, Stuart K. Roberts, Beat Müllhaupt, Tarik Asselah, John-Paul Gallivan, Marcus Schuchmann, Jean-Pierre Bronowicki, Florian Voss, Felix Stickel, Edward Gane, Wulf O. Böcher, Federico J. Mensa, Marc Bourlière, Michael Manns, Peter W Angus, Jerry O. Stern, Vicente Soriano
Publikováno v:
Antimicrobial Agents and Chemotherapy
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2015, 59 (2), pp.1282-1291. ⟨10.1128/AAC.04383-14⟩
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2015, 59 (2), pp.1282-1291. ⟨10.1128/AAC.04383-14⟩
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Patients with advanced hepatic fibrosis or cirrhosis with chronic hepatitis C virus (HCV) infection represent an unmet need. The HCV NS3/4A inhibitor, faldaprevir, was evaluated in combination with the nonnucleoside NS5B inhibitor, deleobuvir, with o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bea72bdb837e015b6a95544ae2f5e41e
https://hal.univ-lorraine.fr/hal-01669250
https://hal.univ-lorraine.fr/hal-01669250
Autor:
Federico J. Mensa, Tarik Asselah, Marc Bourlière, Jerry O. Stern, Beat Müllhaupt, Edward Gane, Wulf O. Böcher, Vicente Soriano, John-Paul Gallivan, Jean-Pierre Bronowicki, Patrick Baum, Marcus Schuchmann, Florian Voss, Stuart K. Roberts, Maria Buti, Stefan Zeuzem, Ansgar W. Lohse
Publikováno v:
PLoS ONE, Vol 10, Iss 12, p e0144004 (2015)
PLoS ONE
PLoS ONE, 2015, 10 (12), ⟨10.1371/journal.pone.0144004⟩
PLoS ONE, Public Library of Science, 2015, 10 (12), ⟨10.1371/journal.pone.0144004⟩
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
PLoS ONE
PLoS ONE, 2015, 10 (12), ⟨10.1371/journal.pone.0144004⟩
PLoS ONE, Public Library of Science, 2015, 10 (12), ⟨10.1371/journal.pone.0144004⟩
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
BACKGROUND & AIM:Whether inosine triphosphatase (ITPA) gene polymorphisms predict anemia during interferon-free therapy in chronic hepatitis C virus (HCV)-infected patients is unknown. We examined the relationship between two ITPA polymorphisms, anem
Autor:
Federico J. Mensa, Tarik Asselah, Marc Bourlière, George Kukolj, Jerry O. Stern, Beat Müllhaupt, Edward Gane, Richard Vinisko, John-Paul Gallivan, Jean-Pierre Bronowicki, Vincent Soriano, Marcus Schuchmann, Stuart K. Roberts, Maria Buti, Stefan Zeuzem, Ansgar W. Lohse, W. Böcher
Interferon-free regimens would be a major advance in the treatment of patients with chronic hepatitis C virus (HCV) infection.In this phase 2b, randomized, open-label trial of faldaprevir (a protease inhibitor) and deleobuvir (a nonnucleoside polymer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55897a8006fcea0dae08c5557eaa1887
https://www.zora.uzh.ch/id/eprint/93375/
https://www.zora.uzh.ch/id/eprint/93375/
Autor:
Christoph Sarrazin, George Kukolj, Jerry O. Stern, Curtis Cooper, Joseph Scherer, Donald M. Jensen, Patrick Ingiliz, Murray Drulak, John-Paul Gallivan, Ira M. Jacobson, Graham R. Foster, Eric M. Yoshida, Anne-Marie Quinson, Douglas T. Dieterich, Michael Schobelock, Vicente Soriano, Peter Ferenci, Mark T. Nelson
Publikováno v:
Gastroenterology. 146:S-976
Autor:
Jean-Pierre Bronowicki, George Kukolj, Jerry O. Stern, Wulf O. Böcher, Federico J. Mensa, Maria Buti, Beat Müllhaupt, Jean-François Dufour, Marc Bourlière, Stefan Zeuzem, Richard Vinisko, Jawahar Taunk, John-Paul Gallivan, Parvez S. Mantry, Robert Buynak
Publikováno v:
Gastroenterology. 146:S-975
Autor:
Christoph Sarrazin, Stefan Zeuzem, Javier Crespo, Joseph Scherer, Armando Abergel, John-Paul Gallivan, Armando Carvalho, Eric M. Yoshida, Shuhei Nishiguchi, Peter Ferenci, Manuel Romero-Gómez, George Kukolj, Jerry O. Stern, Jean-François Dufour, Douglas T. Dieterich, Masao Omata, Donald M. Jensen, Makoto Kuboki, Marc Bourlière, Wulf O. Böcher, Edward Tam, David Wright, Cheng Yuan Peng, Parvez S. Mantry
Publikováno v:
Gastroenterology. 146:S-977
Background: The HCV-PRO is a validated disease-specific patient reported outcome (PRO) instrument. This analysis reports on HCV-infected patient response in a trial of oral DAA therapy and assesses psychometric properties of the French-translated HCV